Breaking News Instant updates and real-time market news.

APU

AmeriGas

$45.16

0.47 (1.05%)

18:08
10/12/16
10/12
18:08
10/12/16
18:08

AmeriGas lowers FY16 adjusted EBITDA view to $540M from $575M-$600M

Sees FY16 net income $205M. The decrease in the earnings guidance is primarily due to an increase in reserves associated with litigation and general liability matters. In addition, weather was 47% warmer than normal during the month of September, the effects of which were not included in previous guidance.

APU AmeriGas
$45.16

0.47 (1.05%)

05/25/16
JANY
05/25/16
INITIATION
Target $50
JANY
Buy
AmeriGas coverage assumed with a Buy at Janney Capital
Target $50.
06/10/16
UBSW
06/10/16
DOWNGRADE
Target $39
UBSW
Sell
AmeriGas downgraded to Sell from Neutral at UBS
UBS analyst Shneur Gershuni downgraded Amerigas Partners LP to Sell saying the stock looks relatively expensive at current levels and that its yield is lower than competitors. The analyst keeps a $39 price target for the shares.
06/10/16
06/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. Zoetis (ZTS) downgraded to Neutral from Buy at Citi by analyst Liav Abraham, who cited valuation, as she views the stock as fairly valued at current levels. The stock has significantly outperformed the specialty pharma group year-to-date, Abraham said, adding that she remains constructive on the company's fundamentals. The analyst increased her price target for shares to $50 from $46. 2. AbbVie (ABBV) downgraded to Market Perform from Outperform by BMO Capital, which cut its target on shares to $66 from $70. In the wake of events at ASCO, disclosures at AbbVie's R&D day, and statements from Eli Lilly (LLY) and Pfizer (PFE), the firm is more concerned about the longer term outlook for AbbVie's immunology franchise, especially Humira. 3. AmeriGas (APU) downgraded to Sell from Neutral at UBS by analyst Shneur Gershuni, who said the stock looks relatively expensive at current levels and that its yield is lower than competitors. The analyst, who kept a $39 price target on shares, also downgraded Ferrellgas Partners (FGP) to Sell and Suburban Propane (SPH) to Neutral. 4. J.M. Smucker (SJM) downgraded to Hold from Buy at Jefferies by analyst Akshay Jagdale, who raised his price target for shares to $143 from $140. The analyst views the stock's risk/reward as balanced at current levels amid rising commodity costs and the management transition. 5. Mattress Firm (MFRM) downgraded to Market Perform from Outperform at Raymond James by analyst Budd Bugatch following the Q1 report and conference call. The analyst said the Sleepy's integration, a move to a new corporate headquarters, and merchandising push to more proprietary products have increased near-term earnings risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/16
JEFF
07/25/16
DOWNGRADE
Target $50
JEFF
Hold
AmeriGas downgraded to Hold from Buy at Jefferies
Jefferies analyst Christopher Sighinolfi downgraded AmeriGas Partners to Hold citing valuation and keeps a $50 price target for the shares. The analyst views the ongoing deceleration in NGL supply growth and recent pullback in product pricing as a bearish shift for the Master Limited Partnerships.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.